Literature DB >> 15072967

Insulin resistance and hypertension.

James R Sowers.   

Abstract

Diminished insulin (Ins) sensitivity is a characteristic feature of various pathological conditions such as the cardiometabolic syndrome, Type 2 diabetes, and hypertension. Persons with essential hypertension are more prone than normotensive persons to develop diabetes, and this propensity may reflect decreased ability of Ins to promote relaxation and glucose transport in vascular and skeletal muscle tissue, respectively. There are increasing data suggesting that ANG II acting through its ANG type 1 receptor inhibits the actions of Ins in vascular and skeletal muscle tissue, in part, by interfering with Ins signally through phosphatidylinositol 3-kinase (PI3K) and its downstream protein kinase B (Akt) signaling pathways. This inhibitory action of ANG II is mediated, in part, through stimulation of RhoA activity and oxidative stress. Activated RhoA and increased reactive oxygen species inhibition of PI3K/Akt signaling results in decreased endothelial cell production of nitric oxide, increased myosin light chain activation with vasoconstriction, and reduced skeletal muscle glucose transport.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15072967     DOI: 10.1152/ajpheart.00026.2004

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  110 in total

1.  A new antihypertensive drug ameliorate insulin resistance.

Authors:  Yan-xia Liu
Journal:  Acta Pharmacol Sin       Date:  2012-04       Impact factor: 6.150

2.  Aging, metabolic syndrome and the heart.

Authors:  Guarner Veronica; Rubio-Ruiz Maria Esther
Journal:  Aging Dis       Date:  2012-03-13       Impact factor: 6.745

3.  Enhanced estradiol-induced vasorelaxation in aortas from type 2 diabetic mice may reflect a compensatory role of p38 MAPK-mediated eNOS activation.

Authors:  Kumiko Taguchi; Akitaka Morishige; Takayuki Matsumoto; Katsuo Kamata; Tsuneo Kobayashi
Journal:  Pflugers Arch       Date:  2012-06-23       Impact factor: 3.657

Review 4.  Metabolic safety of antihypertensive drugs: myth versus reality.

Authors:  Sameer Stas; Lama Appesh; James Sowers
Journal:  Curr Hypertens Rep       Date:  2006-10       Impact factor: 5.369

Review 5.  Angiotensin II-receptor antagonist in the treatment of hypertension.

Authors:  Massimo Volpe; Giuliano Tocci; Erika Pagannone
Journal:  Curr Hypertens Rep       Date:  2005-08       Impact factor: 5.369

6.  Chronic glucose infusion causes sustained increases in tubular sodium reabsorption and renal blood flow in dogs.

Authors:  Michael W Brands; Tracy D Bell; Nancy A Rodriquez; Praveen Polavarapu; Dmitriy Panteleyev
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-12-10       Impact factor: 3.619

7.  Oral ethinylestradiol-levonorgestrel attenuates cardiac glycogen and triglyceride accumulation in high fructose female rats by suppressing pyruvate dehydrogenase kinase-4.

Authors:  Kehinde Samuel Olaniyi; Lawrence Aderemi Olatunji
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-10-01       Impact factor: 3.000

Review 8.  Antihypertensive treatment and new-onset diabetes mellitus.

Authors:  Tonje Amb Aksnes; Henrik M Reims; Sverre E Kjeldsen; Giuseppe Mancia
Journal:  Curr Hypertens Rep       Date:  2005-08       Impact factor: 5.369

9.  D1-like receptors inhibit insulin-induced vascular smooth muscle cell proliferation via down-regulation of insulin receptor expression.

Authors:  Chunyu Zeng; Yu Han; Hefei Huang; Changqing Yu; Hongmei Ren; Weibin Shi; Duofen He; Lan Huang; Chengming Yang; Xukai Wang; Lin Zhou; Pedro A Jose
Journal:  J Hypertens       Date:  2009-05       Impact factor: 4.844

Review 10.  Targeting hypertension in patients with cardiorenal metabolic syndrome.

Authors:  Edward Rojas; Manuel Velasco; Valmore Bermúdez; Zafar Israili; Peter Bolli
Journal:  Curr Hypertens Rep       Date:  2012-10       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.